Finally, Big News From Sarepta Therapeutics
Research - Sarepta Therapeutics (SRPT) will be filing a NDA by the end of this year for eteplirsen. The trade has been good for 150% for those who followed us in early this year.
PremiumAuthor Archives: Editorial Staff
Market Holiday! The Week’s Recap
Insights - The situation gets interesting next week for the biotech sector. Here’s why: A sentiment-shift in relation to biotech. We’re getting into the heart of earnings … Continue Reading
Read now
Albany Molecular Aspires to Grow Revenue Five-Fold in As Many Years
Research - An aggressive growth plan laid out in early 2014 by management has us interested in Albany Molecular Research (AMRI). Click here to read more.
Read nowActivism and Aggressive Planning: Two Themes this Friday
Recap - Neptune Technologies (NEPT) was one of a few green equities in a sea of red on Friday. Why? Some of NEPT’s largest shareholders, a crowd with a history of activism, … Continue Reading
Read nowThis ETF Broke a Major Trendline Today: What’s Next?
Recap - Continued weakness in the healthcare sector this week was marked on Friday by the iShares Biotech Index’s (IBB) break of a key uptrend and support level, suggesting … Continue Reading
Read nowWhere’s the Bottom? Yet Another Tough Week in Bios
Recap - The S&P 500 and the NASDAQ ended the Friday trading session in the green, both nearly flat year-to-date, while the biotech sector continued sliding lower … Continue Reading
Read nowWhat’s with Legislators and Drugs this Week? Weekly Recap
Recap - First, W.V. Democratic Senator Joe Manchin introduced a bill last week to overturn the FDA’s marketing approval of Zohydro ER, an opioid pain product developed by Zogenix Inc. (ZGNX) and approved just last … Continue Reading
Read now